专利扣合机制之前景
对知识产权（IP）的大力保护对生物制药创新十分重要。保护知识产权能够为疾病预防、诊断和治疗吸引和维持长期投资创造激励和商业确定性。然而，没有有效的执法，知识产权将价值甚微。
Contributor
Journalist, Editor
Jack Ellis is a journalist and editor who has written extensively on technology, investment, and innovation-related issues.
From 2014 to 2016, Jack was the Asia-Pacific editor of IAM, responsible for news reporting throughout the region. He has also worked in a number of editorial and research roles covering intellectual property, start-ups, venture capital, and the non-profit sector.
Jack holds a degree from the University of Sheffield in the United Kingdom.
The Promise of Patent Linkage
Countries that want to build an innovation driven knowledge-economy should embrace patent linkage, writes Jack Ellis
Why regulatory data protection matters for medicines
Without regulatory data protection, there will be less investment in developing the ground-breaking biomedical treatments of tomorrow.
Enantiomer patents – a necessary incentive
Understanding how exactly these structurally similar molecules work on the human body requires significant investments of time, money and expertise, write Jack Ellis and Philip Stevens.
Second medical uses for existing drugs
Patents are necessary to incentivise research into this vital area of medicine, write Philip Stevens and Jack Ellis
The power of combination drugs
Combining different drugs into a single pill can have enormous therapeutic benefits but research and development is difficult and costly, write Philip Stevens and Jack Ellis